title: TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts.
abstract: TRANCE (tumor necrosis factor-related activation-induced cytokine) is a recently described member of the tumor necrosis factor superfamily that stimulates dendritic cell survival and has also been found to induce osteoclastic differentiation from hemopoietic precursors. However, its effects on mature osteoclasts have not been defined. It has long been recognized that stimulation of osteoclasts by agents such as parathyroid hormone (PTH) occurs through a hormonal interaction with osteoblastic cells, which are thereby induced to activate osteoclasts. To determine whether TRANCE accounts for this activity, we tested its effects on mature osteoclasts. TRANCE rapidly induced a dramatic change in osteoclast motility and spreading and inhibited apoptosis. In populations of osteoclasts that were unresponsive to PTH, TRANCE caused activation of bone resorption equivalent to that induced by PTH in the presence of osteoblastic cells. Moreover, osteoblast-mediated stimulation of bone resorption was abrogated by soluble TRANCE receptor and by the soluble decoy receptor osteoprotegerin (OPG), and stimulation of isolated osteoclasts by TRANCE was neutralized by OPG. Thus, TRANCE expression by osteoblasts appears to be both necessary and sufficient for hormone-mediated activation of mature osteoclasts, and TRANCE-R is likely to be a receptor for signal transduction for activation of the osteoclast and its survival.
authors.affiliation: St. George's Hospital Medical School, London, United Kingdom.
authors.forename: K
authors.initials: K
authors.lastname: Fuller
authors.forename: B
authors.initials: B
authors.lastname: Wong
authors.forename: S
authors.initials: S
authors.lastname: Fox
authors.forename: Y
authors.initials: Y
authors.lastname: Choi
authors.forename: T J
authors.initials: TJ
authors.lastname: Chambers
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001862:Bone Resorption / Q000235:genetics / Q000276:immunology* / Q000473:pathology; D016827:CD8 Antigens / Q000235:genetics; D002352:Carrier Proteins; D002417:Cattle; D002465:Cell Movement; D006801:Humans; D008562:Membrane Glycoproteins / Q000235:genetics / Q000502:physiology*; D051379:Mice; D010006:Osteoblasts / Q000502:physiology*; D010010:Osteoclasts / Q000502:physiology*; D010281:Parathyroid Hormone / Q000494:pharmacology; D053245:RANK Ligand; D051381:Rats; D053246:Receptor Activator of Nuclear Factor-kappa B; D011993:Recombinant Fusion Proteins / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology*
chemical_list: D016827:CD8 Antigens; D002352:Carrier Proteins; D008562:Membrane Glycoproteins; D010281:Parathyroid Hormone; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D011993:Recombinant Fusion Proteins; C505686:TNFRSF11A protein, human; C505688:TNFSF11 protein, human; C505687:Tnfrsf11a protein, mouse; C505689:Tnfsf11 protein, mouse; D014409:Tumor Necrosis Factor-alpha